Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
Stanley S Schwartz,1,2 Arie Katz3 1University of Pennsylvania, Philadelphia, PA, USA; 2Main Line Health System, Ardmore, PA, USA; 3AstraZeneca, Fort Washington, PA, USA Abstract: In type 2 diabetes (T2D), early combination therapy using agents that target a number of the underlying pathophysiologic...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-03-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/sodiumndashglucose-cotransporter-2-inhibitor-combination-therapy-to-op-peer-reviewed-article-DMSO |
| _version_ | 1797936073724133376 |
|---|---|
| author | Schwartz SS Katz A |
| author_facet | Schwartz SS Katz A |
| author_sort | Schwartz SS |
| collection | DOAJ |
| description | Stanley S Schwartz,1,2 Arie Katz3 1University of Pennsylvania, Philadelphia, PA, USA; 2Main Line Health System, Ardmore, PA, USA; 3AstraZeneca, Fort Washington, PA, USA Abstract: In type 2 diabetes (T2D), early combination therapy using agents that target a number of the underlying pathophysiologic defects contributing to hyperglycemia may improve patient outcomes. For many patients, the combination of metformin with a sodium–glucose cotransporter-2 (SGLT-2) inhibitor may be a good option because these agents have complementary mechanisms of action, neutral-to-positive effects on body weight, and a low risk of hypoglycemia. This review focuses on the combination of metformin with dapagliflozin, a member of the SGLT-2 inhibitor class of antidiabetes agents. In clinical trials, the combination of dapagliflozin with metformin produced significant and sustained reductions in glycated hemoglobin and body weight in a broad range of adult patients with T2D, including those initiating pharmacotherapy and those with more advanced disease. These reductions were accompanied by modest decreases in blood pressure. Dapagliflozin as add-on therapy to metformin was well tolerated and associated with low rates of hypoglycemia. Genital infections and, in some studies, urinary tract infections were more frequent with dapagliflozin than with placebo. Early combination therapy with dapagliflozin and metformin may be a safe and appropriate treatment option that enables patients with T2D to achieve individualized glycemic goals as either initial combination therapy in treatment-naïve patients or as dapagliflozin add-on in patients inadequately controlled with metformin therapy. Keywords: combination therapy, dapagliflozin, metformin |
| first_indexed | 2024-04-10T18:25:05Z |
| format | Article |
| id | doaj.art-f459a502a70e4328a6a2f9aa92ee6fc3 |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T18:25:05Z |
| publishDate | 2016-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-f459a502a70e4328a6a2f9aa92ee6fc32023-02-02T06:25:46ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072016-03-012016Issue 1718225989Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metforminSchwartz SSKatz AStanley S Schwartz,1,2 Arie Katz3 1University of Pennsylvania, Philadelphia, PA, USA; 2Main Line Health System, Ardmore, PA, USA; 3AstraZeneca, Fort Washington, PA, USA Abstract: In type 2 diabetes (T2D), early combination therapy using agents that target a number of the underlying pathophysiologic defects contributing to hyperglycemia may improve patient outcomes. For many patients, the combination of metformin with a sodium–glucose cotransporter-2 (SGLT-2) inhibitor may be a good option because these agents have complementary mechanisms of action, neutral-to-positive effects on body weight, and a low risk of hypoglycemia. This review focuses on the combination of metformin with dapagliflozin, a member of the SGLT-2 inhibitor class of antidiabetes agents. In clinical trials, the combination of dapagliflozin with metformin produced significant and sustained reductions in glycated hemoglobin and body weight in a broad range of adult patients with T2D, including those initiating pharmacotherapy and those with more advanced disease. These reductions were accompanied by modest decreases in blood pressure. Dapagliflozin as add-on therapy to metformin was well tolerated and associated with low rates of hypoglycemia. Genital infections and, in some studies, urinary tract infections were more frequent with dapagliflozin than with placebo. Early combination therapy with dapagliflozin and metformin may be a safe and appropriate treatment option that enables patients with T2D to achieve individualized glycemic goals as either initial combination therapy in treatment-naïve patients or as dapagliflozin add-on in patients inadequately controlled with metformin therapy. Keywords: combination therapy, dapagliflozin, metforminhttps://www.dovepress.com/sodiumndashglucose-cotransporter-2-inhibitor-combination-therapy-to-op-peer-reviewed-article-DMSOcombination therapydapagliflozinmetformin |
| spellingShingle | Schwartz SS Katz A Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin Diabetes, Metabolic Syndrome and Obesity combination therapy dapagliflozin metformin |
| title | Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin |
| title_full | Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin |
| title_fullStr | Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin |
| title_full_unstemmed | Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin |
| title_short | Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin |
| title_sort | sodium ndash glucose cotransporter 2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes focus on dapagliflozin ndash metformin |
| topic | combination therapy dapagliflozin metformin |
| url | https://www.dovepress.com/sodiumndashglucose-cotransporter-2-inhibitor-combination-therapy-to-op-peer-reviewed-article-DMSO |
| work_keys_str_mv | AT schwartzss sodiumndashglucosecotransporter2inhibitorcombinationtherapytooptimizeglycemiccontrolandtolerabilityinpatientswithtype2diabetesfocusondapagliflozinndashmetformin AT katza sodiumndashglucosecotransporter2inhibitorcombinationtherapytooptimizeglycemiccontrolandtolerabilityinpatientswithtype2diabetesfocusondapagliflozinndashmetformin |